Literature DB >> 21757572

Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management.

Shelley Shapiro1, Glenna L Traiger2, Michelle Turner3, Michael D McGoon4, Prieya Wason5, Robyn J Barst6.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) is a life-threatening disease that affects more women than men. The reasons for the female preponderance are unclear, and there are limited data available for men with PAH.
METHODS: Data from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) were analyzed to explore sex differences among patients with PAH with regard to 2-year survival from enrollment and 5-year survival from time of diagnosis.
RESULTS: The data set included 2,318 women and 651 men. More women had PAH associated with connective tissue disease (P < .001), and more men had portopulmonary hypertension (P < .001) and HIV-associated PAH (P < .001). More women had congenital heart disease-associated PAH (P = .017), thyroid disease (P < .001), and depression reported (P ≤ .001). At diagnosis, men had higher mean pulmonary artery pressure (53 ± 14 vs 51 ± 14.3 mm Hg; P = .013) and mean right atrial pressure (10 ± 6 vs 9 ± 6 mm Hg; P = .031). Women had better survival estimates for 2 years from enrollment and for 5 years from diagnosis. Stratifying by age showed that survival from enrollment was similar between men and women aged < 60 years at enrollment, whereas men aged ≥ 60 years have lower survival rates compared with women aged ≥ 60 years.
CONCLUSIONS: Our findings highlight similarities and differences between men and women with PAH, raising questions for future exploration regarding the role of hormones and sex in causation and survival in PAH. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.

Entities:  

Mesh:

Year:  2011        PMID: 21757572     DOI: 10.1378/chest.10-3114

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  69 in total

1.  Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

Authors:  Kirsty M Mair; Audrey F Wright; Nicholas Duggan; David J Rowlands; Martin J Hussey; Sonia Roberts; Josephine Fullerton; Margaret Nilsen; Lynn Loughlin; Matthew Thomas; Margaret R MacLean
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

2.  Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research.

Authors:  Tim Lahm; Steven M Kawut
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 3.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

4.  Sleep disordered breathing in group 1 pulmonary arterial hypertension.

Authors:  Milan Minic; John T Granton; Clodagh M Ryan
Journal:  J Clin Sleep Med       Date:  2014-03-15       Impact factor: 4.062

5.  Sex differences in response to tadalafil in pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Paul M Hassoun; Milo A Puhan; Yi Zhou; Robert A Wise
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

6.  Estrogen receptor-α prevents right ventricular diastolic dysfunction and fibrosis in female rats.

Authors:  Tik-Chee Cheng; Jennifer L Philip; Diana M Tabima; Santosh Kumari; Bakhtiyor Yakubov; Andrea L Frump; Timothy A Hacker; Alessandro Bellofiore; Rongbo Li; Xin Sun; Kara N Goss; Tim Lahm; Naomi C Chesler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

Review 7.  Sex differences in the pulmonary circulation: implications for pulmonary hypertension.

Authors:  Yvette N Martin; Christina M Pabelick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-07       Impact factor: 4.733

8.  Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.

Authors:  Meghan M Cirulis; John J Ryan
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

9.  Sex-specific cardiopulmonary exercise testing parameters as predictors in patients with idiopathic pulmonary arterial hypertension.

Authors:  Ping Yuan; Hui-Juan Ni; Tian-Xiang Chen; Bigyan Pudasaini; Rong Jiang; Hui Liu; Qin-Hua Zhao; Lan Wang; Su-Gang Gong; Jin-Ming Liu
Journal:  Hypertens Res       Date:  2017-06-01       Impact factor: 3.872

Review 10.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.